BidaskClub upgraded shares of Medidata Solutions (NASDAQ:MDSO) from a sell rating to a hold rating in a report released on Tuesday morning.
A number of other brokerages have also weighed in on MDSO. Royal Bank of Canada assumed coverage on shares of Medidata Solutions in a report on Tuesday, September 19th. They issued a sector perform rating and a $82.00 price objective on the stock. Zacks Investment Research upgraded shares of Medidata Solutions from a sell rating to a hold rating in a report on Wednesday, September 20th. SunTrust Banks restated a buy rating and issued a $92.00 price objective on shares of Medidata Solutions in a report on Friday, October 27th. Wells Fargo & Co reduced their price objective on shares of Medidata Solutions from $83.00 to $80.00 and set a market perform rating on the stock in a report on Friday, October 27th. Finally, Dougherty & Co assumed coverage on shares of Medidata Solutions in a report on Thursday, November 2nd. They issued a neutral rating on the stock. One analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the stock. The stock has an average rating of Buy and an average target price of $84.54.
Shares of Medidata Solutions (NASDAQ MDSO) traded up $0.30 on Tuesday, hitting $67.20. 620,700 shares of the stock were exchanged, compared to its average volume of 450,800. Medidata Solutions has a fifty-two week low of $47.77 and a fifty-two week high of $85.92. The firm has a market cap of $3,911.04, a price-to-earnings ratio of 96.00, a price-to-earnings-growth ratio of 3.47 and a beta of 1.69. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.29 and a quick ratio of 3.37.
Medidata Solutions (NASDAQ:MDSO) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.02. Medidata Solutions had a net margin of 7.84% and a return on equity of 11.54%. The business had revenue of $140.08 million for the quarter, compared to analyst estimates of $141.27 million. During the same period last year, the business earned $0.28 EPS. The company’s revenue was up 16.7% on a year-over-year basis. equities research analysts expect that Medidata Solutions will post 0.78 EPS for the current year.
In related news, CFO Rouven Bergmann sold 2,000 shares of Medidata Solutions stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $65.40, for a total transaction of $130,800.00. Following the sale, the chief financial officer now directly owns 91,775 shares in the company, valued at approximately $6,002,085. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carlos Dominguez sold 9,066 shares of Medidata Solutions stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $66.85, for a total transaction of $606,062.10. Following the sale, the director now owns 66,020 shares in the company, valued at $4,413,437. The disclosure for this sale can be found here. Insiders have sold a total of 239,010 shares of company stock worth $16,437,036 over the last quarter. 5.80% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the stock. Summit Creek Advisors LLC acquired a new stake in Medidata Solutions during the 4th quarter worth $5,137,000. KAMES CAPITAL plc grew its position in Medidata Solutions by 54.6% during the 4th quarter. KAMES CAPITAL plc now owns 25,521 shares of the company’s stock worth $1,617,000 after purchasing an additional 9,012 shares during the last quarter. California Public Employees Retirement System grew its position in Medidata Solutions by 1.2% during the 3rd quarter. California Public Employees Retirement System now owns 104,076 shares of the company’s stock worth $8,124,000 after purchasing an additional 1,276 shares during the last quarter. Zions Bancorporation purchased a new position in Medidata Solutions during the 3rd quarter worth $256,000. Finally, Jane Street Group LLC grew its position in Medidata Solutions by 112.8% during the 3rd quarter. Jane Street Group LLC now owns 9,505 shares of the company’s stock worth $742,000 after purchasing an additional 5,038 shares during the last quarter.
About Medidata Solutions
Medidata Solutions Inc (Medidata) is a provider of cloud-based solutions for life sciences. The Company provides cloud-based solutions for clinical research in life sciences, offering platform technology that focuses on the clinical development. The Company’s plan study addresses three areas to ensure optimal study design, grant development and negotiation, and investigator payments.
Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with MarketBeat.com's FREE daily email newsletter.